Last reviewed · How we verify
DGD
DGD is a recombinant protease that selectively debrides necrotic tissue by breaking down denatured collagen and proteins in burn wounds.
DGD is a recombinant protease that selectively debrides necrotic tissue by breaking down denatured collagen and proteins in burn wounds. Used for Enzymatic debridement of eschar in thermal burns, Removal of necrotic tissue in deep partial and full-thickness burn wounds.
At a glance
| Generic name | DGD |
|---|---|
| Sponsor | MediWound Ltd |
| Drug class | Enzymatic debridement agent |
| Target | Denatured collagen and extracellular matrix proteins |
| Modality | Small molecule |
| Therapeutic area | Wound Care / Burn Treatment |
| Phase | Phase 3 |
Mechanism of action
DGD (Desiccated Gamma-Irradiated Bromelain) is an enzymatic debridement agent derived from bromelain that targets and digests only dead, denatured tissue while preserving viable tissue. It works by enzymatically breaking down the extracellular matrix components in eschar and necrotic wound tissue, facilitating their removal without surgical intervention. This selective proteolytic action promotes faster wound healing and reduces the need for surgical debridement in severe burns.
Approved indications
- Enzymatic debridement of eschar in thermal burns
- Removal of necrotic tissue in deep partial and full-thickness burn wounds
Common side effects
- Transient hyperemia/erythema at application site
- Mild pain or discomfort during debridement
- Bleeding or oozing from wound bed
Key clinical trials
- Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns (PHASE2)
- Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |